Leuprolide
Camcevi, Depot, Eligard, Fensolvi, Lupaneta Pack, Lupron, Lupron Depot (leuprolide) is a protein pharmaceutical. Leuprolide was first approved as Lupron on 1985-04-09. It is used to treat breast neoplasms, endometrial neoplasms, endometriosis, infertility, and leiomyoma amongst others in the USA. The pharmaceutical is active against gonadotropin-releasing hormone receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
urogenital diseases | D000091642 |
skin and connective tissue diseases | D017437 |
endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Camcevi, Eligard, Fensolvi, Lupron depot, Lupron depot-ped, Lutrate depot (generic drugs available since 1998-08-04, discontinued: Lupron, Viadur)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Leuprolide acetate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
LUPRON DEPOT | AbbVie | N-019732 RX | 1989-01-26 | 1 products, RLD, RS |
LUPRON DEPOT | AbbVie | N-020011 RX | 1995-10-26 | 1 products, RLD, RS |
LUPRON DEPOT-PED KIT | AbbVie | N-020263 RX | 1993-04-16 | 6 products, RLD, RS |
LUPRON DEPOT | AbbVie | N-020517 RX | 1995-12-22 | 3 products, RLD |
LUPRON DEPOT | AbbVie | N-020708 RX | 1997-03-07 | 1 products, RLD, RS |
LUTRATE DEPOT KIT | Cipla | N-205054 RX | 2018-08-28 | 1 products, RLD, RS |
ELIGARD KIT | Tolmar | N-021343 RX | 2002-01-23 | 1 products, RLD, RS |
ELIGARD KIT | Tolmar | N-021379 RX | 2002-07-24 | 1 products, RLD, RS |
ELIGARD KIT | Tolmar | N-021488 RX | 2003-02-13 | 1 products, RLD, RS |
ELIGARD KIT | Tolmar | N-021731 RX | 2004-12-14 | 1 products, RLD, RS |
Show 1 marketed
Show 4 discontinued
Leuprolide acetate
+
Norethindrone acetate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
LUPANETA PACK | AbbVie | N-203696 DISCN | 2012-12-14 | 2 products, RLD |
Hide discontinued
Leuprolide mesylate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CAMCEVI KIT | Accord Healthcare | N-211488 RX | 2021-05-25 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
camcevi | New Drug Application | 2023-04-03 |
eligard | New Drug Application | 2023-01-09 |
fensolvi | New Drug Application | 2023-02-28 |
lupron depot | New Drug Application | 2023-01-21 |
viadur | 2006-05-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
endometrial neoplasms | EFO_0004230 | D016889 | — |
endometriosis | EFO_0001065 | D004715 | N80 |
infertility | EFO_0000545 | D007246 | — |
leiomyoma | HP_0000131 | D007889 | D25 |
ovarian neoplasms | EFO_0003893 | D010051 | C56 |
precocious puberty | — | D011629 | E22.8 |
prostatic hyperplasia | EFO_0000284 | D011470 | N40 |
prostatic neoplasms | — | D011471 | C61 |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
LEUPROLIDE ACETATE, LUPRON DEPOT-PED KIT, ABBVIE ENDOCRINE INC | |||
2026-04-14 | NS | ||
LEUPROLIDE MESYLATE, CAMCEVI KIT, ACCORD | |||
2024-05-25 | NP | ||
LEUPROLIDE ACETATE, FENSOLVI KIT, TOLMAR | |||
2023-05-01 | I-829 |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Leuprolide Acetate, Lupron Depot, Abbvie Endocrine Inc | |||
8921326 | 2031-02-05 | DP | U-1666 |
Leuprolide Acetate, Lupron Depot-Ped Kit, Abbvie Endocrine Inc | |||
9617303 | 2028-03-22 | U-3611 | |
Leuprolide Mesylate, Camcevi Kit, Accord | |||
9572857 | 2027-01-16 | DP | |
9744207 | 2027-01-16 | DP | |
10646572 | 2027-01-16 | DP | |
Leuprolide Acetate, Eligard Kit, Tolmar | |||
8470359 | 2023-10-15 | DS, DP | U-621, U-2940 |
HCPCS
Code | Description |
---|---|
J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
J1951 | Injection, leuprolide acetate for depot suspension (fensolvi), 0.25 mg |
J1952 | Leuprolide injectable, camcevi, 1 mg |
J9217 | Leuprolide acetate (for depot suspension), 7.5 mg |
J9218 | Leuprolide acetate, per 1 mg |
J9219 | Leuprolide acetate implant, 65 mg |
S9560 | Home injectable therapy; hormonal therapy (e.g.; leuprolide, goserelin), including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gout | D006073 | EFO_0004274 | M10 | 3 | 1 | 6 | 1 | 1 | 12 |
Chronic renal insufficiency | D051436 | N18 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperuricemia | D033461 | — | 1 | — | — | 1 | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 8 | — | — | — | — | 8 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LEUPROLIDE |
INN | leuprorelin |
Description | Leuprolide is an oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. It has a role as an antineoplastic agent, a gonadotropin releasing hormone agonist and an anti-estrogen. |
Classification | Protein |
Drug class | GnRH analogue; GnRH agonist; Antigonadotropin |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1 |
Identifiers
PDB | — |
CAS-ID | 53714-56-0 |
RxCUI | 42375 |
ChEMBL ID | CHEMBL1201199 |
ChEBI ID | 6427 |
PubChem CID | 657181 |
DrugBank | DB00007 |
UNII ID | EFY6W0M8TG (ChemIDplus, GSRS) |
Target
Agency Approved
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Lupron - AbbVie
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,807 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
83 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more